Other equities research analysts have also issued reports about the company. Shore Capital reaffirmed a buy rating on shares of BTG in a research note on Thursday, August 9th. Numis Securities reaffirmed a buy rating on shares of BTG in a research note on Wednesday, July 18th. Finally, Peel Hunt reaffirmed a hold rating and issued a GBX 640 ($8.34) price objective on shares of BTG in a research note on Thursday, August 9th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the company. The company has a consensus rating of Hold and an average target price of GBX 697.50 ($9.09).
LON:BTG opened at GBX 542 ($7.06) on Monday. BTG has a 1 year low of GBX 559.82 ($7.29) and a 1 year high of GBX 784 ($10.21).
In other BTG news, insider Anne Thorburn purchased 15,000 shares of the firm’s stock in a transaction that occurred on Monday, July 23rd. The stock was purchased at an average cost of GBX 500 ($6.51) per share, with a total value of £75,000 ($97,694.41). Also, insider Dame Pamela Louise Makin sold 73,410 shares of the firm’s stock in a transaction that occurred on Tuesday, July 17th. The stock was sold at an average price of GBX 488 ($6.36), for a total value of £358,240.80 ($466,641.66).
BTG plc acquires, develops, manufactures, and commercializes pharmaceutical products in the United States, Europe, and internationally. It operates through three segments: Interventional Medicine, Pharmaceuticals, and Licensing. The Interventional Medicine segment offers interventional oncology products and systems, such as beads and TheraSphere for treatment of liver cancer; and GALIL medical system, a cryoablation technology for use in kidney cancer and other indications.
Further Reading: Earnings Per Share (EPS)
Receive News & Ratings for BTG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG and related companies with MarketBeat.com's FREE daily email newsletter.